Role of upadacitinib in addressing unmet needs in RA
24 Mar 2021
byDr. Tommy Tsang Cheung, Specialist in Rheumatology , Hong Kong Sanatorium & Hospital
Despite considerable advances in rheumatoid arthritis (RA) therapy over the past decades, remission rates remain suboptimal. In an interview with MIMS Doctor, Dr Tommy Tsang Cheung, Specialist in Rheumatology at the Hong Kong Sanatorium & Hospital, discussed common challenges in achieving optimal disease control and presented clinical data demonstrating superiority of the Janus kinase (JAK) inhibitor, upadacitinib, over the commonly used second-line biologic disease-modifying antirheumatic drug (bDMARD), adalimumab, in reaching RA treatment goals.
